Controlling the spread of carbapenemase-producing Gram-negatives: Therapeutic approach and infection control

Clinical Microbiology and Infection

Volumn 16, Issue 2, 2010, Pages 102-111

  Carmeli, Y ^a   Akova, M ^b   Cornaglia, G ^c   Daikos, G L ^d   Garau, J ^e   Harbarth, S ^f   Rossolini, G M ^g,h   Souli, M ⁱ   Giamarellou, H ⁱ  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b HACETTEPE UNIVERSITY   (Turkey)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF ATHENS   (Greece)

^e HOSPITAL MÚTUA DE TERRASSA   (Spain)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g UNIVERSITY OF SIENA   (Italy)

^h UNIVERSITY HOSPITAL OF SIENA   (Italy)

ⁱ UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antimicrobial resistance; Carbapenemases; Gram negatives; Infection control; Metallo lactamases; Review; Therapy

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM; BETA LACTAMASE INHIBITOR; CARBAPENEM; CARBAPENEMASE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; ERTAPENEM; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LACTOFERRIN I; LACTOFERRIN II; MEROPENEM; METALLO BETA LACTAMASE; NXL 104; PENICILLIN G; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; BLOODSTREAM INFECTION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENTIATION; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; IN VITRO STUDY; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATITIS; PROSTHETIC VALVE ENDOCARDITIS; PUBLIC HEALTH; RETROPERITONEAL ABSCESS; REVIEW;

ENTEROBACTERIACEAE; NEGIBACTERIA;

EID: 74549155155     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.03115.x     Document Type: Review

References (63)

1. Bellais S, Mimoz O, Léotard S. Efficacy of beta-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-beta-lactamase-producing strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002, 46:2032-2034.
2. Oie S, Fukui Y, Yamamoto M. In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo β-lactamase-producing Pseudomonas aeruginosa. BMC Infect Dis 2009, 9:123.
3. Sader HS, Rhomberg PR, Jones RN. In vitro activity of beta-lactam antimicrobial agents in combination with aztreonam tested against metallo-beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter baumannii. J Chemother 2005, 17:622-627.
4. Miyajima Y, Hiramatsu K, Mizukami E. In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa. Int J Antimicrob Agents 2008, 32:437-440.
5. Tripodi M-F. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug resistant Acinetobacter baumannii. Int J Antimicrob Agents 2007, 30:537-540.
6. Montero A, Ariza J, Corbella X. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004, 54:1085-1091.
7. Daikos GL, Panagiotakopoulou A, Tzelepi E. Activity of imipenem against VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model. Clin Microbiol Infect 2007, 13:202-205.
8. Souli M, Konstantinidou E, Tzepi I. Are carbapenems effective against carbapenem-susceptible, metallo-b-lactamase producing Enterobacteriaceae? Results from an animal model. J Antimicrob Chemother (submitted)
9. Panagiotakopoulou A, Daikos GL, Miriagou V. Comparative in vitro killing of carbapenems and aztreonam against Klebsiella pneumoniae producing VIM-1 metallo-β-lactamase. Int J Antimicrob Agents 2007, 29:360-362.
10. Souli M, Rekatsina P, Chryssouli Z. Does the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-β-lactamase-producing Klebsiella pneumoniae isolates? Antimicrob Agents Chemother 2009, 53:2133-2135.
11. Mushtaq S, Ge Y, Livermore DL. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob Agents Chemother 2004, 48:1113-1119.
12. Marti S, Sánchez-Céspedes J, Alba V, Vila J. In vitro activity of doripenem against Acinetobacter baumannii clinical isolates. Int J Antimicrob Agents 2009, 33:181-182.
13. Souli M, Kontopidou FV, Koratzanis E. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006, 50:3166-3169.
14. Pliatsika V, Afkou Z, Protonotariou E, Sofianou D. In vitro activity of tigecycline against metallo-b-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2007, 60:1406-1407.
15. Castanheira M, Sader HS, Deshpande LM. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008, 52:570-573.
16. Bratu S, Tolaney P, Karumudi U. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005, 56:128-132.
17. Souli M, Galani I, Antoniadou A. An outbreak of KPC-2-producing Klebsiella pneumoniae in a Greek university hospital: molecular characterization, epidemiology and outcomes. Clin Infect Dis 2009
18. Livermore DM, Mushtaq S, Warner M. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J Antimicrob Chemother 2008, 62:1053-1056.
19. Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 2009, 53:3599-3601.
20. Stachyra T, Levasseur P, Péchereau MC. In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 2009, 64:326-329.
21. Koga T, Sugihara C, Kakuta M. Affinity of tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009, 53:1238-1241.
22. Dijkshoorn L, Brouwer CP, Bogaards SJ. The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004, 48:4919-4921.
23. Zhang JF, Chen BL, Xin XY. Carbapenem resistance mechanism and risk factors of Pseudomonas aeruginosa clinical isolates from a university hospital in Xi'an, China. Microb Drug Resist 2009, 15:41-45.
24. Tam VH, Chang KT, LaRocco MT. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2007, 58:309-314.
25. Cornaglia G, Akova M, Amicosante G. Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int J Antimicrob Agents 2007, 29:380-388.
26. Zavascki AP, Barth AL, Gaspareto PB. Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-beta-lactamase in two tertiary-care teaching hospitals. J Antimicrob Chemother 2006, 58:882-885.
27. Nouér SA, Nucci M, de-Oliveira MP. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother 2005, 49:3663-3667.
28. Miriagou V, Cornaglia G, Edelstein M. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect 2010, 16:112-122.
29. Zavascki AP, Barth AL, Gonçalves AL. The influence of metallo-beta-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections. J Antimicrob Chemother 2006, 58:387-392.
30. Marra AR, Pereira CA, Gales AC. Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes. Antimicrob Agents Chemother 2006, 50:388-390.
31. Souli M, Kontopidou FV, Papadomichelakis E. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek university hospital. Clin Infect Dis 2008, 46:847-854.
32. Herbert S, Halvorsen DS, Leong T. Large outbreak of infection and colonization with gram-negative pathogens carrying the metallo-beta-lactamase gene blaIMP-4 at a 320-bed tertiary hospital in Australia. Infect Control Hosp Epidemiol 2007, 28:98-101.
33. Daikos GL, Karabinis A, Paramythiotou. VIM-1-producing Klebsiella pneumoniae bloodstream infections: analysis of 28 cases. Int J Antimicrob Agents 2007, 29:471-473.
34. Bratu S, Landman D, Haag R. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005, 165:1430-1435.
35. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009, 9:228-236.
36. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008, 52:1028-1033.
37. Patel G, Huprikar S, Factor SH. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008, 29:1099-1106.
38. Woodford N, Tierno PM, Young K. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York medical center. Antimicrob Agents Chemother 2004, 48:4793-4799.
39. Maltezou HC, Giakkoupi P, Maragos A. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect 2009, 58:213-219.
40. Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 2008, 52:1413-1418.
41. Saito T, Takaori-Kondo A, Tashima M. Successful treatment with intravenous colistin for sinusitis, orbital cellulitis, and pneumonia caused by multidrug-resistant metallo-beta-lactamase-producing Pseudomonas aeruginosa in a patient with acute myeloid leukemia. Int J Hematol 2009, 89:689-692.
42. Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2007, 51:3413-3415.
43. Rahal JJ, Urban C, Segal-Maurer S. Nosocomial antibiotic resistance in multiple gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clin Infect Dis 2002, 34:409-503.
44. Kato Y, Ohashi H, Tsutsumi Y. Prosthetic valve endocarditis caused by metallo-beta-lactamase-producing Pseudomonas aeruginosa. J Card Surg 2009, 24:347-349.
45. Falagas ME, Kanellopoulou MD, Karageorgopoulos DE. Antimicrobial susceptibility of multidrug-resistant Gram-negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis 2008, 27:439-443.
46. Guerin F, Henegar C, Spiridon G. Bacterial prostatitis due to Pseudomonas aeruginosa harbouring the blaVIM-2 metallo-beta-lactamase gene from Saudi Arabia. J Antimicrob Chemother 2005, 56:601-602.
47. Peleg AY, Franklin C, Bell JM, Spelman DW. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis 2005, 41:1549-1556.
48. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008, 62:895-904.
49. Poulakou G, Kontopidou FV, Paramythiotou. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect 2009, 58:273-284.
50. Daikos GL, Petrikkos P, Psichogiou M. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009, 53:1868-1873.
51. Michalopoulos A, Virtzili S, Rafailidis P. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010, 16:184-186.
52. Lee NY, Yan JJ, Lee HC. Clinical experiences of bacteremia caused by metallo-beta-lactamase-producing gram-negative organisms. J Microbiol Immunol Infect 2004, 37:343-349.
53. Weisenberg SA, Morgan DJ, Espinal-Witter R, Larone DH. Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn Microbiol Infect Dis 2009, 64:233-235.
54. Schwaber MJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA 2008, 300:2911-2913.
55. Wertheim HF, Vos MC, Boelens HA. Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect 2004, 56:321-325.
56. Kluytmans-Vandenbergh MF, Kluytmans JA, Voss A. Dutch guideline for preventing nosocomial transmission of highly resistant microorganisms (HRMO). Infection 2005, 33:309-313.
57. Urban C, Bradford PA, Tuckman M. Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities. Clin Infect Dis 2008, 46:127-130.
58. Lledo W, Hernandez M, Lopez E. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR 2009, 58:256-260.
59. Kochar S, Sheard T, Sharma R. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2009, 30:447-452.
60. Endimiani A, Depasquale JM, Forero S. Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J Antimicrob Chemother 2009, Sep 9 [Epub ahead of print]
61. Rooney PJ, O'Leary MC, Loughrey AC. Nursing homes as a reservoir of extended-spectrum b-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother 2009, 64:635-641.
62. Tsakris A, Ikonomidis A, Poulou A. Transmission in the community of clonal Proteus mirabilis carrying VIM-1 metallo-beta-lactamase. J Antimicrob Chemother 2007, 60:136-139.
63. Tsakris A, Ikonomidis A, Spanakis N. Characterization of In3Mor, a new integron carrying VIM-1 metallo-beta-lactamase and sat1 gene, from Morganella morganii. J Antimicrob Chemother 2007, 59:739-741.